Another collaboration to fight cancer!
A NEW PROJECT TO HELP DEVELOP THERAPEUTIC ANTIBODIES TO FIGHT HARD-TO-TREAT CANCERS
JUNE 14, 2018
The Cancer Research Society is proud to contribute jointly with Immune Biosolutions, CQDM, Mitacs, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke and TransfertTech, to allow the teams of professors Fernand Gobeil, Philippe Sarret and Fernand-Pierre Gendron of Université de Sherbrooke to develop innovative therapeutic antibodies. This research aims to improve treatment options for certain types of cancer that remain difficult to treat.
The highly specific anti-cancer antibodies developed during the project will target solid cancers, such as colorectal and non-small cell lung cancers, as well as prostate and triple negative breast cancers. In Canada, nearly 50% of all cancer-related deaths can be attributed to these four types of cancer: lung, colorectal, breast, and prostate.
“We are very excited about this project as it aims to find solutions to some hard-to-treat cancers. It is important for us to support the research and development of personalized and less invasive treatments for patients,”
says Max Fehlmann, President and Chief Executive Officer of the Cancer Research Society.
The research team will also develop biomarkers tests for early cancer detection and monitoring of treatment efficacy, which is critical for patients.
Read the Consortium québécois sur la découverte du médicament (CQDM) press release